

PAPER

View Article Online
View Journal | View IssueCrossMark
click for updatesCite this: *RSC Adv.*, 2015, 5, 23311Received 13th January 2015
Accepted 24th February 2015

DOI: 10.1039/c5ra00759c

www.rsc.org/advances

Chemical synthesis of the tumor-associated globo H antigen†

Satadru S. Mandal, Guochao Liao and Zhongwu Guo*

A derivative of the tumor-associated globo H antigen, a complex hexasaccharide, was synthesized by a convergent and efficient [3 + 2 + 1] strategy using various glycosylation methods. All glycosylation reactions afforded good to excellent yields and outstanding stereoselectivity, including the installation of *cis* α -linked D-galactose and L-fucose. The longest linear sequence for this synthesis was 11 steps from a galactose derivative **11** to give an overall yield of 2.6%. The synthetic target had a free and reactive amino group at the glycan reducing end, facilitating its conjugation with other molecules for various applications.

Introduction

Carbohydrates are abundantly displayed on the surface of both normal and tumor cells as glycoconjugates, such as glycolipids, glycoproteins, and so on. The special glycans expressed by cancer cells, which are known as tumor-associated carbohydrate antigens (TACAs), are useful molecular targets for the development of new cancer therapeutics and diagnostics. For example, the globo H antigen, a hexasaccharyl sphingolipid (**1**, Fig. 1), was first isolated by Hakomori and colleagues from the breast cancer cell line MCF-7.^{1–3} It was later discovered on many other tumors, especially breast, prostate and lung cancer, as well.⁴ Therefore, globo H has become an important target for anticancer vaccine development.^{5–12} It has been disclosed that the conjugates of globo H with proteins, such as keyhole limpet hemocyanin (KLH), could elicit strong immune responses in mice⁶ and humoral immune responses in cancer patients,¹³ demonstrating promising results in clinical trials as vaccines against breast and prostate cancer.^{12,13} As a result, the synthesis of globo H antigen has attracted significant attention in the past decades.¹²




Fig. 1 Structure of tumor-associated globo H antigen.

Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, Michigan 48202, USA. E-mail: zwguo@chem.wayne.edu; Tel: +1-313-577-2557


† Electronic supplementary information (ESI) available: Additional experimental procedures for the synthesis of compounds **11**, **8**, **4**, and **15**, and NMR and MS spectra for all of the isolated intermediates and products. See DOI: 10.1039/c5ra00759c

Globo H was first assembled by Danishefsky and co-workers using the glycal strategy,^{14,15} which was subsequently refined.¹⁶ Other elegant syntheses include Schmidt's synthesis based on trichloroacetimidate glycosylation,¹⁷ Boon's synthesis employing a two-directional glycosylation strategy,¹⁸ Wong's reactivity based one-pot synthesis,^{19,20} Huang's thioglycoside pre-activation based one-pot synthesis,²¹ Wang's enzymatic synthesis,²² and Seeberger's linear and solid-phase syntheses,^{23,24} as well as the synthesis of globo H fragments.^{25,26} In spite of the great progress in total synthesis of globo H, currently it is still difficult to access, especially in the form suitable for further elaborations, thus scientist has to rely on oneself to prepare it for any investigation. As a consequence, new synthetic strategies for globo H are still desirable.

In an effort to explore TACA-based anticancer vaccines, we describe herein an efficient synthesis for a globo H derivative **2** (Scheme 1), which carried a free amino group at the glycan reducing end. It would facilitate the conjugation of this carbohydrate antigen with other molecules, such as vaccine carriers like KLH or monophosphoryl lipid A derivatives – a new type of vaccine carriers that are being explored in our laboratory,^{27,28} through simple linkers that do not have ill influence on the immunological properties of the resultant glycoconjugates.²⁹ This synthesis is highlighted by combined application of different glycosylation methods to effect the assembly of specific glycosidic linkages.

Results and discussion

As depicted in Scheme 1, successive retrosynthetic disconnections of the glycosidic bonds in the target molecule **2** resulted in monosaccharide building blocks **4**, **7**, **8** and **9**, as well as a lactose derivative **10**. Special attentions were paid to the two relatively challenging 1,2-*cis*-glycosidic linkages of Gal III and Fuc VI. Therefore, monosaccharides **4** and **9**, instead of their oligosaccharide blocks, were utilized as glycosyl donors for



Scheme 1 Structure of the designed globo H derivative 2 and its retrosynthetic plan.


constructing these glycosidic bonds. Moreover, the 2-O-positions of 4 and 9 were protected with the non-participating benzyl (Bn) group. On the other hand, the 2-O-positions of 7 and 8, as well as the resultant disaccharide 5, were protected with the participating benzoyl (Bz) and phthalyl (Phth) groups to guarantee stereoselective 1,2-*trans*-glycosylation reactions. Monosaccharides 7 and 8 would be coupled first to form disaccharide 5 as a building block to further improve the convergence and efficiency of the designed synthesis. Building block 10 may be readily prepared from lactose *via* a series of regioselective transformations.

The project commenced with the development of a new, concise and efficient route for the synthesis of 7³⁰ and 9^{31,32} (Scheme 2), using 11^{33,34} as the common intermediate prepared from free D-galactose *via* a series of conventional reactions including peracetylation, thioglycosylation, deacetylation, and regioselective acetal formation at the 4,6-O-positions. In both syntheses, a key step was the tin complex directed regioselective alkylation to give 3-O-alkylated products 12 and 13. Benzoylation of 12 readily afforded glycosyl donor 7. On the other hand, benzoylation of 13 followed by oxidative hydrolysis of the thioglycoside in 14 and then trichloroacetimidation of the resultant


hemiacetal gave glycosyl donor 9 ($\alpha : \beta$ 12 : 1) in an excellent overall yield (42%) from 11.

The synthesis of the disaccharide building block 10 (Scheme 3) started from lactose which was first converted into 15 according to a literature procedure.^{35,36} Selective protection of the *cis* 4'-O- and 6'-O-positions in 15 with the benzylidene ring was carried out successfully by treating 15 with benzaldehyde dimethyl acetal and camphor sulfonic acid (CSA) to afford 16 in a 74% yield. Perbenzylation of the remaining free hydroxyl groups in 16 was followed by regioselective reductive ring opening of the 4':6'-O-benzylidene acetal in the resultant 17 to expose the 4'-OH and offer the desired building block 10 smoothly.


To construct the disaccharide building block 5 (Scheme 4), we conducted the glycosylation of 8, which was prepared from galactosamine by a reported procedure,³⁰ with 7 at -5°C in dichloromethane using methyl trifluoromethanesulfonate (MeOTf) as the promoter. While TLC indicated that the reaction was clean, to our surprise, it gave the unwanted α -disaccharide 18 as the predominant product ($\alpha : \beta$ 9 : 1), in spite of the presence of a participating Bz group at the 2-O-position of 7. A potential explanation for this result was that the presence of benzylidene rings in the donor and acceptor somehow decreased their reactivities to facilitate $\text{S}_{\text{N}}2$ type of reaction. To deal with the problem, we converted thioglycoside donor 7 into the more reactive trichloroacetimidate 19 in two steps, including treating 7 with *N*-iodosuccinimide (NIS) and silver triflate (AgOTf) in wet dichloromethane and then with trichloroacetonitrile in the presence of 1,8-diazabicycloundec-7-ene (DBU) to get mainly α -imidate ($\alpha : \beta$ 12 : 1). Glycosylation of 8 with 19 proceeded smoothly in the presence of trimethyl trifluoromethanesulfonate (TMSOTf) to give the desired β -disaccharide 4 ($J_{\text{H-1}',\text{H-2}'} = 8.1\text{ Hz}$) as the major product ($\alpha : \beta$ 1 : 10) in a good yield (75%). Then, we attempted to selectively remove the 2'-O-benzoyl group in 5 using sodium methoxide in methanol, hoping that the fucose residue could be introduced at this stage to obtain a trisaccharide fragment for the target



Scheme 2 Synthesis of glycosyl donors 7 and 9.



Scheme 3 Synthesis of the disaccharide building block 10.




Scheme 4 Synthesis of the disaccharide building block 5.

hexasaccharide assembly by a highly convergent [3 + 3] strategy. Surprisingly, the reaction was complex even when only a catalytic amount of sodium methoxide was used. It was possible that the Phth group was affected under this condition. Consequently, we directly employed 5 as a glycosyl donor for the assembly of the target molecule by a [3 + 2 + 1] strategy.

Next, our attention was focused on the installation of Gal III α -linked to Gal II (Scheme 5), which was one of the major challenges in the synthesis of globo H antigen, because in general it is relatively difficult to create the *cis* α -galactosidic linkage and the galactose axial 4-OH shows relatively low nucleophilicity. To cope with this issue, in addition to using the nonparticipating Bn group for 2-O-protection in donor 9, we also executed the glycosylation reaction employing a unique experimental procedure of reversed addition, *i.e.*, slowly adding

donor 9 to the solution of acceptor 10 and promoter TMSOTf at -70 °C. The reaction afforded the desired α -trisaccharide 6 ($J_{H-1'',H-2''} = 3.2$ Hz) in a good yield (58%) and excellent stereo-selectivity ($\alpha : \beta$ 15 : 1). Selective removal of the 3''-O-*para*-methoxybenzyl (PMB) group in 6 with DDQ gave trisaccharide 20 as a glycosyl acceptor in an 86% yield.

The coupling reaction between 5 and 20 was accomplished smoothly in CH_2Cl_2 at -30 °C with NIS and AgOTf as promoters. The reaction was stereospecific to generate the β -anomer 3 only ($J_{H-1'',H-2''} = 7.8$ Hz), probably due to the participation of the neighboring 2-*N,N*-Phth group in donor 5 in the glycosylation. Again, attempts to selectively remove the Bz group at the Gal V 2-O-position in 3 were unsuccessful. Therefore, we decided to remove the 2-*N,N*-Phth protection and install the desired *N*-acetyl group at this stage, instead of at the final global deprotection step, and concomitantly remove the 2'''-O-Bz group. Refluxing 3 with hydrazine hydrate ($NH_2NH_2 \cdot H_2O$) in ethanol removed the Phth and Bz groups smoothly and cleanly (monitored by TLC and MS). The freed amino group and hydroxyl group were acetylated under routine conditions, which was followed by selective removal of the 2'''-O-acetyl group with sodium methoxide in methanol to give 21 as a glycosyl acceptor. Finally, fucosylation of 21 with thioglycoside donor 4^{26,37} using NIS and TfOH as promoters resulted in stereospecific formation of the desired hexasaccharide 22 ($J_{H-Fuc-1,2} = 3.7$ Hz) in a good yield (70%). We also transformed 4 into its corresponding trichloroacetimidate and tested it as a donor to react with acceptor 3 using TMSOTf as promoter; however, this reaction gave the desired hexasaccharide 22 in a very poor yield (15%). Clearly, the results of a glycosylation extensively depend on the donors used in the reaction. Attempted global deprotection of 22 to



Scheme 5 Assembly of the target molecule 2 from various building blocks.

remove all of the benzylidene and Bn groups in one step by hydrogenolysis gave rather complex results, and the main side reactions were partial debenzylidenation as noticed by MS analysis. Consequently, we switched to a two-step protocol for the global deprotection, including the removal of all benzylidene groups in acetic acid and water (5 : 1) at 60 °C and then hydrogenolysis to remove all of the Bn groups with concomitant reduction of the azido group to a free primary amine, to yield the target molecule **2**, which was fully characterized with both 1D, 2D NMR and HR MS.

In conclusion, a convergent and highly efficient [3 + 2 + 1] strategy was developed for the synthesis of a derivative of the globo H antigen. Different glycosylation methods were explored for generating the glycosidic linkages, so as to establish optimal conditions for the synthesis. As a consequence, all of the glycosylation reactions offered good to excellent yields and outstanding stereoselectivity, including the reactions to install the rather challenging *cis* α -linked D-galactose and L-fucose. Eventually, the target molecule **2** was prepared from a galactose derivative **11** in 11 steps and a 2.6% overall yield, which represented the longest linear synthetic sequence. The good overall yield of the current synthesis would make it feasible to prepare the title compound in relatively large quantities. Moreover, the target molecule **2** carried a free amino group at the glycan reducing end that can be selectively elaborated in the presence of free hydroxyl groups. It would facilitate regioselective conjugation of **2** with other molecules, thus it can be useful for various biological studies and applications.

Experimental section

General methods

Chemicals and materials were obtained from commercial sources and were used as received without further purification unless otherwise noted. 4 Å molecular sieves (MS) were flame-dried under high vacuum and used immediately after cooling under a N₂ atmosphere. Analytical TLC was carried out on silica gel 60 Å F₂₅₄ plates with detection by a UV detector and/or by charring with 15% (v/v) H₂SO₄ in EtOH. NMR spectra were recorded on a 400, 500, or 600 MHz machine with chemical shifts reported in ppm (δ) downfield from tetramethylsilane (TMS) that was used as an internal reference.

Ethyl 3-O-phenylmethyl-4:6-O-phenylmethylene-1-thio- β -D-galactopyranoside **12**³³

After the mixture of **11**³³ (4.0 g, 12.8 mmol) and Bu₂SnO (3.83 g, 15.4 mmol) in anhydrous toluene (50 mL) was refluxed in a flask equipped with a Dean–Stark device to remove water for 6 h, the solvent was evaporated under reduced pressure. The residue was mixed with CsF (5.84 g, 38.46 mmol) and BnBr (2.28 mL, 19.2 mmol) in DMF (20 mL) and stirred at rt for 12 h. After the reaction was complete as indicated by TLC, DMF was removed under reduced pressure. The residue was dissolved in CH₂Cl₂ and washed with 1 M aq. NaF solution. The organic phase was dried over Na₂SO₄ and condensed, and the residue was purified by flash column chromatography (acetone–hexane 1 : 9, v/v) to

produce **12** (4.28 g, 83%) as colorless syrup. ¹H NMR (400 MHz, CDCl₃): δ 7.58–7.54 (m, 2H, ArH), 7.40–7.35 (m, 8H, ArH), 5.45 (s, 1H, CHPh), 4.77 (s, 2H, CH₂Ph), 4.36 (d, *J* = 9.6 Hz, 1H, H-1), 4.31 (dd, *J* = 12.0, 1.6 Hz, 1H, H-6), 4.18 (d, *J* = 2.4 Hz, 1H, H-4), 4.07 (t, *J* = 9.6 Hz, 1H, H-2), 3.97 (dd, *J* = 12.0, 1.6 Hz, 1H, H-6'), 3.50 (dd, *J* = 9.6, 4.0 Hz, 1H, H-3), 3.41 (s, 1H, H-5), 2.89–2.69 (m, 2H, SCH₂CH₃), 2.58 (bs, 1-OH), 1.33 (t, *J* = 7.6 Hz, 3H, SCH₂CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 138.0, 133.3, 130.2, 128.5, 128.0, 127.9, 126.8, 101.6, 83.1, 78.3, 73.7, 71.3, 70.4, 69.7, 69.0, 23.0, 15.1.

Ethyl 2-O-benzoyl-3-O-phenylmethyl-4:6-O-phenylmethylene-1-thio- β -D-galactopyranoside **7**³⁰

After a solution of **12** (4.1 g, 10.1 mmol), Et₃N (2.8 mL, 20.4 mmol), BzCl (1.42 mL, 12.2 mmol) and a few drop of DMAP in anhydrous CH₂Cl₂ (30 mL) was stirred at rt overnight, the reaction mixture was washed with saturated aq. NaHCO₃ solution (3 × 10 mL) followed by drying over Na₂SO₄. The desired product **7** was obtained as colorless syrup (4.3 g, 84%) after flash column chromatography (acetone–hexane 1 : 10, v/v). ¹H NMR (400 MHz, CDCl₃): δ 8.04 (d, *J* = 6.5 Hz, 2H, ArH), 7.62–7.54 (m, 3H, ArH), 7.50–7.44 (m, 2H, ArH), 7.42–7.35 (m, 3H, ArH), 7.27–7.16 (m, 5H, ArH), 5.74 (t, *J* = 9.7 Hz, 1H, H-2), 5.52 (s, 1H, CHPh), 4.66 (q, *J* = 12.9 Hz, 2H, CH₂Ph), 4.55 (d, *J* = 9.7 Hz, 1H, H-1), 4.36 (d, *J* = 12.9 Hz, 1H, H-6), 4.28 (d, *J* = 3.2 Hz, 1H, H-4), 4.02 (d, *J* = 12.9 Hz, 1H, H-6'), 3.75 (dd, *J* = 9.7, 3.2 Hz, 1H, H-3), 3.47 (s, 1H, H-5), 2.98–2.87 (m, 1H, SCH₂CH₃), 2.82–2.72 (m, 1H, SCH₂CH₃), 1.28 (t, *J* = 6.5 Hz, 3H, SCH₂CH₃); ¹³C NMR (100 MHz, CDCl₃): δ 165.3, 137.8, 137.7, 129.9, 129.1, 128.3, 128.2, 127.8, 127.7, 126.5, 101.4, 73.4, 71.0, 70.1, 69.4, 68.7, 22.7, 14.9; HRMS (ESI TOF): calcd for C₂₉H₃₀NaO₆S [M + Na]⁺ *m/z*, 529.1661; found, 529.1668.

2-O-Benzoyl-3-O-phenylmethyl-4:6-O-phenylmethylene- α -D-galactopyranosyl trichloroacetimidate **19**

After a mixture of **7** (2.0 g, 3.95 mmol), TTBP (2.94 g, 11.8 mmol), NIS (1.77 g, 7.9 mmol) and AgOTf (2.03 g, 7.9 mmol) was stirred in wet CH₂Cl₂ (15 mL) at 0 °C for 2 h, the reaction mixture was allowed to warm up to rt and stirred for another 4 h. The reaction mixture was quenched with saturated aq. Na₂S₂O₃ solution (10 mL) at 0 °C, and the mixture was diluted with CH₂Cl₂ and washed with brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated in vacuum. The residue was purified by flash column chromatography (acetone–hexane 1 : 4, v/v) to afford the hemiacetal as a white solid (1.38 g, 76%, an anomeric mixture with α as the major product), which was directly applied to the next reaction. DBU (4 drop) was added to a solution of the above product (1.3 g, 2.8 mmol) and trichloroacetonitrile (1.1 mL, 14.05 mmol) in anhydrous CH₂Cl₂ (15 mL), and the solution was stirred under an Ar atmosphere at 0 °C for 1 h. The reaction mixture was concentrated in vacuum, and the product was purified with a Et₃N neutralized silica gel column to get **19** (1.42 g, 81%) as a white solid. ¹H NMR (400 MHz, CDCl₃): δ 8.49 (s, 1H, –NH), 7.79 (d, *J* = 8.1 Hz, 2H, ArH), 7.61–7.54 (m, 3H, ArH), 7.46–7.35 (m, 5H, ArH), 7.34–7.29 (m, 2H, ArH), 7.28–7.23 (m, 3H, ArH), 6.77 (d, *J*

= 3.2 Hz, 1H, H-1), 5.74 (dd, J = 11.3, 3.2 Hz, 1H, H-2), 5.58 (s, 1H, CHPh), 4.74 (q, J = 12.9 Hz, 2H, CH_2Ph), 4.43 (d, J = 3.2 Hz, 1H, H-4), 4.34 (d, J = 12.9 Hz, 1H, H-6), 4.28 (dd, J = 11.3, 3.2 Hz, 1H, H-3), 4.08 (d, J = 12.9 Hz, 1H, H-6'), 3.94 (s, 1H, H-5); ^{13}C NMR (100 MHz, CDCl_3): δ 165.6, 160.4, 137.5, 137.4, 133.3, 129.8, 129.4, 129.2, 128.4, 128.38, 128.32, 128.1, 128.0, 126.4, 101.2, 95.0, 73.6, 72.6, 71.7, 69.2, 68.9, 65.4.

Ethyl 3-*O*-(*para*-methoxyphenyl)methyl-4:6-*O*-phenylmethylene-1-thio- β -D-galactopyranoside 13³¹

It was prepared according to the same procedure used to prepare **12** except for replacing BnCl with PMBCL for the alkylation reaction. Starting from 4.0 g of **11** (12.8 mmol) and 2.6 mL of PMBCL (19.2 mmol), 4.58 g of **13** (83%) was obtained as colorless syrup. ^1H NMR (400 MHz, CDCl_3): δ 7.56 (d, J = 6.8 Hz, 2H, ArH), 7.40–7.31 (m, 5H, ArH), 6.86 (d, J = 8.0 Hz, 2H, ArH), 5.44 (s, 1H, CHPh), 4.69 (q, J = 12.9 Hz, 2H, PhCH_2), 4.35 (d, J = 8.8 Hz, 1H, H-1), 4.31 (dd, J = 13.2, 1.6 Hz, 1H, H-6), 4.16 (d, J = 3.2 Hz, 1H, H-4), 4.04 (t, J = 8.8 Hz, 1H, H-2), 3.97 (dd, J = 13.2, 1.6 Hz, 1H, H-6'), 3.79 (s, 3H, $-\text{OCH}_3$), 3.47 (dd, J = 8.8, 3.2 Hz, 1H, H-3), 3.41 (s, 1H, H-5), 3.88–3.69 (m, 2H, SCH_2CH_3), 1.32 (t, J = 7.6 Hz, 3H, SCH_2CH_3); ^{13}C NMR (100 MHz, CDCl_3): δ 159.4, 137.9, 130.1, 129.5, 129.0, 128.2, 126.4, 101.3, 85.3, 79.9, 73.5, 71.1, 70.1, 69.4, 68.0, 55.3, 22.9, 15.3.

Ethyl 2-*O*-benzoyl-3-*O*-(*para*-methoxyphenyl)methyl-4:6-*O*-phenylmethylene-1-thio- β -D-galactopyranoside 14³²

To a solution of **13** (4.5 g, 10.4 mmol) dissolved in anhydrous DMF was added NaH (275 mg, 11.45 mmol) at 0 °C. After 45 min of stirring, BnBr (1.85 mL, 15.62 mmol) was added to the reaction mixture at 0 °C, and the reaction mixture was stirred for 6 h. When TLC showed that the reaction was completed, the reaction was quenched with H_2O at 0 °C, and the mixture was diluted with EtOAc. The aq. layer was extracted with EtOAc (5 \times 20 mL), and the organic phases were combined and dried over Na_2SO_4 . The solvent was removed under reduced pressure, and the residue was purified by flash column chromatography (acetone–hexane 1 : 11, v/v) to obtain **14** (4.38 g, 81%) as colorless syrup. ^1H NMR (400 MHz, CDCl_3): δ 7.56 (d, J = 6.5 Hz, 2H, ArH), 7.48–7.26 (m, 10H, ArH), 6.86 (d, J = 8.1 Hz, 2H, ArH), 5.49 (s, 1H, CHPh), 4.88 (q, J = 12.9 Hz, 2H, CH_2Ph), 4.71 (s, 2H, CH_2Ph), 4.45 (d, J = 9.7 Hz, 1H, H-1), 4.31 (d, J = 11.3 Hz, 1H, H-6), 4.14 (d, J = 3.2 Hz, 1H, H-4), 3.97 (d, J = 11.3 Hz, 1H, H-6'), 3.89 (t, J = 9.7 Hz, 1H, H-2), 3.81 (s, 3H, $-\text{OCH}_3$), 3.59 (dd, J = 9.7, 3.2 Hz, 1H, H-3), 3.35 (s, 1H, H-5), 3.93–3.83 (m, 1H, SCH_2CH_3), 3.82–3.72 (m, 1H, SCH_2CH_3), 1.35 (t, J = 6.5 Hz, 3H, SCH_2CH_3); ^{13}C NMR (100 MHz, CDCl_3): δ 159.3, 138.4, 138.0, 130.3, 129.4, 129.1, 128.4, 128.3, 128.2, 127.7, 127.6, 126.6, 113.8, 101.5, 84.4, 80.7, 76.9, 75.7, 74.0, 71.4, 69.8, 69.4, 55.3, 23.8, 15.1; HRMS (ESI TOF): calcd for $\text{C}_{30}\text{H}_{34}\text{NaO}_6\text{S} [\text{M} + \text{Na}]^+ m/z$, 545.1974; found, 545.1972.

2-*O*-Benzoyl-3-*O*-(*para*-methoxyphenyl)methyl-4:6-*O*-phenylmethylene- α -D-galactopyranosyl trichloroacetimidate 9

It was prepared according to the procedure used to prepare **7**. Starting from 2.15 g of **11** (9.58 mmol), 1.77 g of **9** (81%) was

obtained as a white solid. ^1H NMR (400 MHz, CDCl_3): δ 8.58 (s, 1H, $-\text{NH}$), 7.55–7.50 (m, 2H, ArH), 7.41–7.24 (m, 10H, ArH), 6.84 (d, J = 9.7 Hz, 2H, ArH), 6.63 (d, J = 3.2 Hz, 1H, H-1), 5.51 (s, 1H, CHPh), 4.82–4.69 (m, 4H, $2 \times \text{CH}_2\text{Ph}$), 4.31–4.22 (m, 3H, H-2, H-6, H-6'), 4.08 (dd, J = 9.7, 3.2 Hz, 1H, H-3), 4.01 (dd, J = 11.3, 3.2 Hz, 1H, H-4), 3.84–3.82 (s, 1H, H-5); ^{13}C NMR (100 MHz, CDCl_3): δ 161.0, 159.2, 138.4, 137.6, 130.2, 129.8, 129.1, 128.3, 128.2, 127.5, 127.4, 127.3, 113.7, 101.2, 95.6, 75.1, 74.6, 74.0, 73.1, 72.0, 69.1, 65.3, 55.3.

2-Azidoethyl 4:6-*O*-phenylmethylene- β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranoside 16³⁵

The solution of **15**³⁵ (4.15 g, 10.1 mmol), benzaldehyde dimethyl acetal (1.82 mL, 12.10 mmol) and CSA (585 mg, 2.5 mmol) dissolved in anhydrous acetonitrile (50 mL) was stirred at rt with occasional vacuum application until TLC showed that the reaction was complete. The reaction was quenched with Et_3N (0.7 mL, 5.04 mmol), and the mixture was diluted with CH_2Cl_2 (30 mL) and washed with brine. The organic phase was dried over anhydrous Na_2SO_4 and concentrated in vacuum. The residue was purified by flash column chromatography ($\text{MeOH}-\text{CH}_2\text{Cl}_2$, 1 : 9, v/v) to give **16** as a white floppy solid (3.74 g, 74.2%). ^1H NMR (400 MHz, CDCl_3): δ 7.55–7.50 (m, 2H, ArH), 7.38–7.31 (m, 3H, ArH), 5.61 (s, 1H, CHPh), 4.48 (d, J = 7.8 Hz, 1H, H-1), 4.35 (d, J = 7.8 Hz, 1H, H-1'), 4.23–4.12 (m, 3H, H-6a', H-4', H-6b'), 4.03–3.97 (m, 1H, H-6b), 3.92–3.89 (m, 2H, H-4, $\text{OCH}_2\text{CH}_2\text{N}_3$), 3.77–3.70 (m, 1H, $\text{OCH}_2\text{CH}_2\text{N}_3$), 3.68–3.55 (m, 4H, H-3, H-6a, H-3', H-5'), 3.49–3.40 (m, 3H, H-2, $\text{OCH}_2\text{CH}_2\text{N}_3$), 3.34 (bs, $-\text{OH}$), 3.32–3.25 (m, 2H, H-2', H-5); ^{13}C NMR (100 MHz, CDCl_3): δ 138.1, 128.5, 127.6, 126.1, 103.4, 102.9, 100.8, 78.6, 75.9, 75.1, 74.8, 73.4, 72.1, 70.3, 68.8, 68.0, 66.9, 60.3, 50.6.

2-Azidoethyl 2,3-di-*O*-phenylmethyl-4:6-*O*-phenylmethylene- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-phenylmethyl- β -D-glucopyranoside 17³⁶

To the solution of **16** (3.7 g, 7.41 mmol) dissolved in anhydrous DMF (30 mL) was added NaH (1.07 g, 44.44 mmol) at 0 °C. The mixture was stirred at 0 °C for 45 min, and then BnBr (6.16 mL, 51.85 mmol) was added. After stirring for another 12 h when TLC showed that the reaction was completed, it was quenched with H_2O at 0 °C, and the mixture was diluted with EtOAc. The aqueous layer was extracted with EtOAc (5 \times 25 mL), and the organic phases were combined and dried over Na_2SO_4 . The desired product **17** (6.24 g, 89%) was obtained upon flash column chromatography (acetone–hexane 1 : 10, v/v) of the condensed product. ^1H NMR (400 MHz, CDCl_3): δ 7.76–7.19 (m, 30H, aromatic), 5.48 (s, 1H, CHPh), 5.21 (d, J = 10.8 Hz, 1H, CH_2Ph), 4.94 (d, J = 11.0 Hz, 1H, CH_2Ph), 4.87 (d, J = 11.2 Hz, 1H, CH_2Ph), 4.83–4.73 (m, 5H, CH_2Ph), 4.56 (d, J = 12.2 Hz, 1H, CH_2Ph), 4.48 (d, J = 7.8 Hz, 1H, H-1), 4.44 (d, J = 7.8 Hz, 1H, H-1'), 4.34 (d, J = 12.0 Hz, 1H, CH_2Ph), 4.22 (d, J = 12.2 Hz, 1H, H-6b'), 4.09–4.03 (m, 2H, H-4, H-6b), 3.99 (t, J = 9.0 Hz, 1H, H-6a'), 3.92–3.84 (m, 2H, H-4', $\text{OCH}_2\text{CH}_2\text{N}_3$), 3.78 (t, J = 9.3 Hz, 1H, H-2), 3.76–3.69 (m, 2H, H-6a, $\text{OCH}_2\text{CH}_2\text{N}_3$), 3.36 (t, J = 9.0 Hz, 1H, H-2'), 3.56–3.36 (m, 5H, H-3, H-5, H-3', $\text{OCH}_2\text{CH}_2\text{N}_3$), 2.96 (s, 1H, H-5'); ^{13}C NMR (100 MHz, CDCl_3): δ 138.9; 138.8, 138.6,

138.5, 138.4, 138.1, 128.6, 128.4, 128.3, 128.2, 128.14, 128.11, 128.0, 127.75, 127.73, 127.6, 127.5, 127.4, 127.3, 126.6, 103.7, 102.9, 101.4, 82.9, 81.8, 81.2, 79.7, 78.8, 77.6, 75.8, 75.3, 75.15, 75.10, 73.6, 73.0, 71.6, 68.9, 68.3, 68.1, 66.4, 51.0; MALDI TOF MS (positive mode): calcd for $C_{56}H_{59}N_3NaO_{11}$ $[M + Na]^+$ m/z , 972.41; found, 972.491.

2-Azidoethyl 2,3,6-tri-*O*-phenylmethyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-phenylmethyl- β -D-glucopyranoside **10**³⁶

After the mixture of **17** (2.0 g, 2.1 mmol), $NaBH_3CN$ (1.24 g, 21.05 mmol) and 4 Å MS (6 g) in dry THF (30 mL) was stirred at rt for 2 h, it was cooled to 0 °C, and then HCl (1 M in dry ether) was added dropwise until pH reached 2. The reaction mixture was stirred at 0 °C for 4 h and at rt for 8 h. When TLC showed that the reaction was completed, Et_3N (1.5 mL) was added to terminate the reaction. Molecular sieves were filtered off through a Celite pad and washed with CH_2Cl_2 (25 mL). The filtrate and washings were combined and washed with saturated aq. $NaHCO_3$ solution and brine, dried over Na_2SO_4 and condensed in vacuum. The residue was purified by flash column chromatography (acetone–hexane 1 : 11, v/v) to give **8** as a white floppy solid (1.42 g, 70.9%). 1H NMR (400 MHz, $CDCl_3$): δ 7.45–7.20 (m, 30H, ArH), 5.01 (d, J = 11.3 Hz, 1H, CH_2Ph), 4.92 (d, J = 11.3 Hz, 1H, CH_2Ph), 4.84–4.66 (m, 6H, CH_2Ph), 4.56 (d, J = 12.2 Hz, 1H, CH_2Ph), 4.50–4.38 (m, 6H, H-1, H-1', H-4', CH_2Ph), 4.10–3.94 (m, 4H, H-4, H-6b, H-6a', $OCH_2CH_2N_3$), 3.82 (dd, J = 10.5, 4.1 Hz, 1H, H-6b'), 3.76–3.57 (m, 4H, H-2, H-3', H-6a, $OCH_2CH_2N_3$), 3.55–3.32 (m, 6H, H-2', H-3, H-5, H-5', $OCH_2CH_2N_3$); ^{13}C NMR (100 MHz, $CDCl_3$): δ 139.1; 138.7, 138.3, 138.2, 137.9, 128.6, 128.5, 128.4, 128.2, 128.1, 127.9, 127.8, 127.7, 127.66, 127.63, 127.3, 103.7, 102.6, 82.8, 81.8, 81.2, 79.4, 77.4, 76.6, 75.4, 75.3, 75.1, 73.6, 73.2, 72.1, 68.5, 68.3, 68.2, 66.2, 51.0; HRMS (ESI TOF): calcd for $C_{56}H_{61}N_3NaO_{11}$ $[M + Na]^+$ m/z , 974.4204; found, 974.4194.

para-Tolyl 2-*O*-benzoyl-3-*O*-phenylmethyl-4:6-*O*-phenylmethylene- β -D-galactopyranosyl-(1 \rightarrow 3)-2-deoxy-4:6-*O*-phenylmethylene-2-phthalimido-1-thio- β -D-galactopyranoside **5**

The mixture of **19** (1.42 g, 2.26 mmol), **8** (950 mg, 1.89 mmol), and 4 Å MS (3.0 g) in CH_2Cl_2 (20 mL) was stirred at rt under an Ar atmosphere for 1 h. After being cooled to –78 °C, TMSOTf (3.42 μ L, 0.019 mmol) was added, and the reaction was stirred at –65 °C for 2 h. When TLC showed that the reaction was completed, saturated aq. $NaHCO_3$ was added to quench the reaction, and it was then diluted with CH_2Cl_2 . Molecular sieves were removed by passing through a Celite pad. After extraction of the aq. layer with CH_2Cl_2 (3 \times 10 mL), the combined organic phase was dried over Na_2SO_4 and concentrated in vacuum, and the residue was purified by silica gel flash column chromatography (acetone–hexane 1 : 11, v/v) to give **4** (1.34 g, 75%) as colorless syrup. $[\alpha]_D^{25}$ = +22.1° (c 2.0, $CHCl_3$). 1H NMR (600 MHz, $CDCl_3$): δ 7.72–7.69 (m, 2H, ArH), 7.67–7.64 (m, 1H, ArH), 7.60–7.50 (m, 5H, ArH), 7.49–7.45 (m, 1H, ArH), 7.39–7.34 (m, 5H, ArH), 7.28–7.11 (m, 9H, ArH), 7.08–7.05 (m, 3H, ArH), 7.00–6.97 (m, 2H, ArH), 5.59 (d, J = 10.3 Hz, 1H, H-1), 5.44 (t, J = 8.8 Hz, 1H, H-2'), 5.38 (s, 1H, CHPh), 5.30 (s, 1H, CHPh), 4.89 (dd, J = 10.3, 3.7 Hz, 1H, H-3), 4.80 (d, J = 8.1 Hz, 1H, H-1'), 4.67 (t, J = 10.3 Hz, 1H, H-2), 4.52 (d, J = 13.2 Hz, 1H, CH_2Ph), 4.48–4.46

(m, 1H, H-4), 4.42 (d, J = 13.2 Hz, 1H, CH_2Ph), 4.32 (d, J = 11.7 Hz, 1H, H-6b), 4.07 (d, J = 2.9 Hz, 1H, H-4'), 3.98 (d, J = 12.5 Hz, 1H, H-6a), 3.79 (d, J = 11.7 Hz, 1H, H-6b'), 3.63–3.57 (m, 2H, H-5, H-6a'), 3.54 (dd, J = 9.5, 2.9 Hz, 1H, H-3'), 3.19 (s, 1H, H-5), 2.27 (s, 3H, $SPhCH_3$); ^{13}C NMR (150 MHz, $CDCl_3$): δ 168.6, 166.8, 164.9, 137.9, 137.8, 137.7, 133.8, 133.7, 133.5, 132.8, 131.7, 131.5, 129.6, 129.4, 129.1, 128.6, 128.3, 128.2, 127.9, 127.6, 127.5, 126.8, 126.6, 123.3, 123.0, 101.5, 101.1, 100.0, 99.9, 83.0, 82.9, 77.2, 75.2, 73.1, 73.0, 72.6, 70.7, 70.5, 70.2, 69.3, 68.7, 66.7, 50.6, 21.2; HRMS (ESI TOF): calcd for $C_{55}H_{49}NNaO_{12}S$ $[M + Na]^+$ m/z , 970.2873; found, 970.2879.

2-Azidoethyl 3-*O*-(*para*-methoxyphenyl)methyl-2-*O*-phenylmethyl-4:6-*O*-phenylmethylene- α -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-phenylmethyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-phenylmethyl- β -D-glucopyranoside **6**

After the mixture of **10** (1.4 g, 1.47 mmol) and 4 Å MS (4 g) in CH_2Cl_2 (20 mL) was stirred at rt under an Ar atmosphere for 1 h, it was then cooled to –78 °C. Then, TMSOTf (2.66 μ L, 0.015 mmol) was added, which was followed by dropwise addition of **9** (1.74 g, 2.79 mmol) dissolved in anhydrous CH_2Cl_2 . The reaction was stirred at the same temperature for 2 h. When TLC showed the reaction was completed, saturated aq. $NaHCO_3$ solution was added to quench the reaction, and then CH_2Cl_2 was added for dilution. Molecular sieves were removed by passing through a Celite pad. After extraction of the aqueous layer with CH_2Cl_2 (3 \times 10), the combined organic phase was dried over Na_2SO_4 and concentrated in vacuum, and the product was purified by silica gel column chromatography (acetone–hexane 1 : 11, v/v) to afford **6** (1.2 g, 58%, colorless syrup as the only trisaccharide). $[\alpha]_D^{25}$ = +26.7° (c 1.2, $CHCl_3$). 1H NMR (400 MHz, $CDCl_3$): δ 7.47–7.40 (m, 4H, ArH), 7.38–7.15 (m, 38H, ArH), 6.83–6.78 (m, 2H, ArH), 5.32 (s, 1H, CHPh), 5.13 (d, J = 3.2 Hz, 1H, H-1''), 5.09 (d, J = 11.3 Hz, 1H, CH_2Ph), 4.89 (d, J = 11.3 Hz, 1H, CH_2Ph), 4.84–4.82 (m, 1H, CH_2Ph), 4.81–4.79 (m, 2H, CH_2Ph), 4.78–4.75 (m, 2H, CH_2Ph), 4.74–4.71 (m, 1H, CH_2Ph), 4.70–4.68 (m, 1H, CH_2Ph), 4.89 (dd, J = 11.3, 9.7 Hz, 2H, CH_2Ph), 4.51–4.46 (m, 3H, H-1', H-6b'', CH_2Ph), 4.42 (d, J = 8.1 Hz, 1H, H-1), 4.37 (d, J = 11.3 Hz, 1H, CH_2Ph), 4.32 (d, J = 11.3 Hz, 1H, CH_2Ph), 4.23 (d, J = 11.3 Hz, 1H, CH_2Ph), 4.20–4.09 (m, 2H, H-4'', H-6b'), 4.07–3.93 (m, 5H, H-2'', H-3'', H-4, H-4', $OCH_2CH_2N_3$), 3.87–3.78 (m, 1H, H-6a''), 3.76 (s, 3H, OCH_3), 3.74–3.38 (m, 11H, H-2' H-3, $OCH_2CH_2N_3$, H-5'', H-6b, H-2, H-5', H-3', H-6a', $OCH_2CH_2N_3$), 3.37–3.27 (m, 2H, H-6a, H-5); ^{13}C NMR (100 MHz, $CDCl_3$): δ 159.3, 139.1, 138.6, 138.5, 138.4, 138.2, 130.8, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.7, 127.6, 127.5, 127.4, 127.0, 126.4, 113.6, 103.6, 103.1, 101.0, 100.8, 82.4, 81.7, 81.3, 78.6, 75.7, 75.4, 75.2, 75.1, 74.9, 73.8, 73.1, 71.9, 71.3, 69.3, 68.3, 68.1, 67.2, 62.9, 55.2, 51.0; MALDI TOF MS (positive mode): calcd for $C_{84}H_{89}N_3NaO_{17}$ $[M + Na]^+$ m/z , 1435.62; found, 1435.20; and HRMS (ESI TOF): calcd for $C_{84}H_{89}N_3NaO_{17}$ $[M + Na]^+$ m/z , 1434.6090; found, 1434.6093.

2-Azidoethyl 2-*O*-phenylmethyl-4:6-*O*-phenylmethylene- α -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-phenylmethyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-phenylmethyl- β -D-glucopyranoside **20**

After the mixture of **6** (1.0 g, 0.708 mmol) and DDQ (322 mg, 1.42 mmol) in CH_2Cl_2 and H_2O (9 : 1, 12 mL) was stirred at 0 °C

for 1 h, it was poured into saturated aq. NaHCO_3 solution (50 mL). The mixture was extracted with CH_2Cl_2 (3×10 mL), and the organic layer was washed with saturated aq. NaHCO_3 solution (3×10 mL) and water (50 mL), dried over Na_2SO_4 , and then concentrated in vacuum. The crude product was purified with silica gel column chromatography (acetone–hexane 1 : 11, v/v) to give **20** (790 mg, 86.3%) as colorless syrup. $[\alpha]_{\text{D}}^{25} = +16.5^\circ$ (*c* 1.73, CHCl_3). ^1H NMR (500 MHz, CDCl_3): δ 7.43–7.37 (m, 4H, ArH), 7.36–7.28 (m, 20H, ArH), 7.27–7.19 (m, 16H, ArH), 5.38 (s, 1H, CHPh), 5.19 (d, $J = 3.7$ Hz, 1H, H-1''), 5.06 (d, $J = 11.7$ Hz, 1H, CH_2Ph), 4.89 (d, $J = 11.0$ Hz, 1H, CH_2Ph), 4.86 (d, $J = 11.7$ Hz, 1H, CH_2Ph), 4.81–4.75 (m, 3H, CH_2Ph), 4.71 (t, $J = 11.0$ Hz, 2H, CH_2Ph), 4.65 (d, $J = 12.5$ Hz, 1H, CH_2Ph), 4.59 (d, $J = 12.5$ Hz, 1H, CH_2Ph), 4.54 (d, $J = 11.7$ Hz, 1H, CH_2Ph), 4.48 (d, $J = 7.30$ Hz, 1H, H-1), 4.42 (d, $J = 7.30$ Hz, 1H, H-1'), 4.38 (d, $J = 12.5$ Hz, 1H, CH_2Ph), 4.31 (d, $J = 11.7$ Hz, 1H, CH_2Ph), 4.25 (d, $J = 11.7$ Hz, 1H, CH_2Ph), 4.19–4.14 (m, 1H, H-6a''), 4.13–4.07 (m, 3H, H-4', H-4'', $\text{OCH}_2\text{CH}_2\text{N}_3$), 4.06–4.01 (m, 2H, H-4, H-3''), 3.97 (t, $J = 9.5$ Hz, 1H, H-2''), 3.83 (dt, $J = 11.7, 3.7$ Hz, 2H, H-6b'', H-6b'), 3.75–3.67 (m, 2H, H-6a', $\text{OCH}_2\text{CH}_2\text{N}_3$), 3.62 (t, $J = 9.5$ Hz, 1H, H-2'), 3.59–3.62 (m, 2H, H-5'', H-6b), 3.51–3.38 (m, 6H, H-2, H-3, H-5', H-3', $\text{OCH}_2\text{CH}_2\text{N}_3$), 3.35–3.29 (m, 2H, H-6a, H-5); ^{13}C NMR (125 MHz, CDCl_3): δ 139.3, 138.6, 138.4, 138.3, 138.2, 138.1, 137.7, 129.0, 128.5, 128.46, 128.40, 128.3, 128.2, 128.17, 128.14, 128.12, 127.9, 127.7, 127.66, 127.61, 127.59, 127.55, 127.2, 127.1, 126.3, 103.6, 102.9, 100.9, 100.3, 82.6, 81.7, 81.3, 78.7, 76.8, 76.4, 75.12, 75.10, 74.98, 74.92, 74.0, 73.8, 73.17, 73.13, 72.9, 72.1, 69.2, 68.7, 68.4, 68.1, 67.2, 62.8, 51.0; MALDI TOF MS (positive mode): calcd for $\text{C}_{76}\text{H}_{81}\text{N}_3\text{NaO}_{16} [\text{M} + \text{Na}]^+ m/z$, 1315.47; found, 1316.402; and HRMS (ESI TOF): calcd for $\text{C}_{76}\text{H}_{81}\text{N}_3\text{NaO}_{16} [\text{M} + \text{Na}]^+ m/z$, 1314.5515; found, 1314.5515.

2-Azidoethyl 2-O-benzoyl-3-O-phenylmethyl-4:6-O-phenylmethylen-β-D-galactopyranosyl-(1 → 3)-2-deoxy-4:6-O-phenylmethylen-2-phthalimido-β-D-galactopyranosyl-(1 → 3)-2-O-phenylmethyl-4:6-O-phenylmethylen-α-D-galactopyranosyl-(1 → 4)-2,3,6-tri-O-phenylmethyl-β-D-galactopyranosyl-(1 → 4)-2,3,6-tri-O-phenylmethyl-β-D-glucopyranoside 3

After the mixture of **5** (917 mg, 0.967 mmol), **20** (500 mg, 0.387 mmol) and **4** Å MS (3 g) in CH_2Cl_2 (20 mL) was stirred at rt under an Ar atmosphere for 1 h, it was cooled to -50°C , and then NIS (261 mg, 1.16 mmol) and AgOTf (298 mg, 1.16 mmol) were added. The mixture was allowed to warm up to -30°C and was stirred at this temperature for 2 h. When TLC showed the completion of reaction, saturated aq. NaHCO_3 solution was added to quench the reaction, and CH_2Cl_2 was then added for dilution. Molecular sieves were removed by passing the mixture through a Celite pad. After extraction with CH_2Cl_2 (3×10), the organic phases were combined and washed with saturated aq. $\text{Na}_2\text{S}_2\text{O}_3$ solution, dried over Na_2SO_4 , and then concentrated in vacuum. The crude product was purified by silica gel column chromatography (acetone–hexane 1 : 9, v/v) to afford **3** (530 mg, 64.6%) as colorless syrup. $[\alpha]_{\text{D}}^{25} = +6.8^\circ$ (*c* 0.8, CHCl_3). ^1H NMR (400 MHz, CDCl_3): δ 7.70 (d, $J = 6.8$ Hz, 2H, ArH), 7.62–7.58 (m, 2H, ArH), 7.53–7.49 (m, 2H, ArH), 7.44–7.19 (m, 44H, ArH), 7.15–7.02 (m, 12H, ArH), 6.92 (d, $J = 7.8$ Hz, 2H, ArH), 5.55–5.47

(m, 1H), 5.46 (s, 1H, CHPh), 5.44 (s, 1H, CHPh), 5.43 (d, $J = 7.8$ Hz, 1H, H-1'''), 5.33 (s, 1H, CHPh), 5.02 (d, $J = 10.8$ Hz, 1H, CH_2Ph), 4.97 (d, $J = 3.9$ Hz, 1H, H-1''), 4.94 (d, $J = 11.7$ Hz, 1H, CH_2Ph), 4.90 (d, $J = 11.7$ Hz, 1H, CH_2Ph), 4.86 (d, $J = 7.80$ Hz, 1H, H-1'''), 4.84 (d, $J = 7.80$ Hz, 1H, H-1'), 4.83 (d, $J = 11.7$ Hz, 1H, CH_2Ph), 4.79 (d, $J = 10.8$ Hz, 1H, CH_2Ph), 4.77 (d, $J = 11.7$ Hz, 1H, CH_2Ph), 4.75 (d, $J = 10.8$ Hz, 1H, CH_2Ph), 4.73 (d, $J = 10.8$ Hz, 1H, CH_2Ph), 4.71 (d, $J = 11.7$ Hz, 1H, CH_2Ph), 4.56 (d, $J = 12.7$ Hz, 1H, CH_2Ph), 4.54 (d, $J = 11.7$ Hz, 1H, CH_2Ph), 4.52 (d, $J = 12.7$ Hz, 1H, CH_2Ph), 4.48 (d, $J = 12.7$ Hz, 1H, CH_2Ph), 4.46 (d, $J = 11.7$ Hz, 1H, CH_2Ph), 4.45 (d, $J = 7.8$ Hz, 1H, H-1), 4.40–4.31 (m, 3H), 4.29–4.26 (m, 1H), 4.25–4.23 (m, 1H), 4.19–4.17 (m, 1H), 4.16–4.05 (m, 4H), 4.04–3.92 (m, 4H), 3.91–3.80 (m, 4H), 3.78–3.70 (m, 3H), 3.69–3.38 (m, 9H), 3.32–3.20 (m, 4H), 2.87–2.84 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 168.6, 167.0, 164.9, 139.1, 138.7, 138.6, 138.3, 138.3, 138.26, 138.23, 138.0, 137.9, 137.8, 137.7, 133.4, 133.2, 132.6, 131.5, 131.4, 129.7, 129.6, 129.1, 128.7, 128.6, 128.4, 128.32, 128.30, 128.2, 128.1, 128.0, 127.9, 127.83, 127.80, 127.7, 127.6, 127.58, 127.51, 127.3, 127.1, 126.7, 126.4, 126.2, 122.8, 103.6, 103.3, 101.5, 100.9, 100.2, 99.9, 98.9, 82.2, 81.8, 81.4, 78.8, 77.3, 77.2, 75.4, 75.3, 75.2, 75.0, 74.9, 74.88, 74.81, 74.3, 73.5, 73.3, 73.1, 72.8, 72.1, 71.9, 70.8, 69.2, 69.0, 68.8, 68.4, 68.1, 67.3, 66.7, 66.1, 63.2, 52.6, 51.0; MALDI TOF MS (positive mode): calcd for $\text{C}_{124}\text{H}_{122}\text{N}_4\text{NaO}_{28} [\text{M} + \text{Na}]^+ m/z$, 2139.310; found, 2138.771; and HRMS (ESI TOF): calcd. for $\text{C}_{124}\text{H}_{122}\text{N}_4\text{NaO}_{28} [\text{M} + \text{Na}]^+ m/z$, 2137.8143; found, 2137.8213.

2-Azidoethyl 3-O-phenylmethyl-4:6-O-phenylmethylen-β-D-galactopyranosyl-(1 → 3)-2-acetamido-2-deoxy-4:6-O-phenylmethylen-β-D-galactopyranosyl-(1 → 3)-2-O-phenylmethyl-4:6-O-phenyl-methylen-α-D-galactopyranosyl-(1 → 4)-2,3,6-tri-O-phenylmethyl-β-D-galactopyranosyl-(1 → 4)-2,3,6-tri-O-phenylmethyl-β-D-glucopyranoside 21

After the solution of **3** (0.50 g, 0.63 mmol) and $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ (3.5 mL) in EtOH (10 mL) was refluxed for *ca.* 6 h, MALDI TOF MS [positive mode: calcd. for $\text{C}_{109}\text{H}_{116}\text{N}_4\text{O}_{25} [\text{M} + \text{Na}]^+ m/z$, 1905.1; found, 1905.0] showed that both the Phth group and the Bz group were completely removed. The mixture was concentrated in vacuum, and the residue was dissolved in anhydrous acetic anhydride (5 mL) and pyridine (5 mL). The solution was stirred at rt for 5 h, and at this point, MALDI TOF MS [positive mode: calcd for $\text{C}_{113}\text{H}_{120}\text{N}_4\text{O}_{27} [\text{M} + \text{Na}]^+ m/z$, 1989.1; found, 1988.7] showed the complete acetylation of the hydroxyl and amino group. The solution was concentrated in vacuum, co-evaporated twice with anhydrous toluene (5 mL), and then dried under high vacuum for 1 h. The solid residue (1.35 g, 3.37 mmol) was dissolved in MeOH (5 mL), to which was added the $\text{CH}_3\text{ONa}/\text{CH}_3\text{OH}$ solution (0.4 M) until pH reached 9.5. Thereafter, the reaction mixture was heated to 70°C for another 6 h, and MALDI TOF MS [positive mode: calcd for $\text{C}_{111}\text{H}_{119}\text{N}_4\text{O}_{26} [\text{M} + \text{Na}]^+ m/z$, 1947.1; found, 1947.3] showed complete *O*-deacetylation. The reaction mixture was neutralized to pH 6–7 using Amberlyst (H^+) resin and then concentrated in vacuum. The crude product was purified by flash column chromatography (acetone–hexane, 1 : 7, v/v) to give **21** as a white solid (240 mg,

54%). $[\alpha]_D^{25} = +14.6^\circ$ (*c* 0.53, CHCl₃). ¹H NMR (600 MHz, CDCl₃): δ 7.52–7.45 (m, 6H, ArH), 7.39–7.18 (m, 48H, ArH), 7.13 (d, *J* = 7.3 Hz, 2H, ArH), 5.56 (d, *J* = 6.6 Hz, 1H, –NHAc), 5.52 (s, 1H, CHPh), 5.43 (s, 1H, CHPh), 5.41 (s, 1H, CHPh), 5.11 (d, *J* = 3.2 Hz, 1H, H-1''), 4.99 (d, *J* = 11.0 Hz, 1H), 4.93 (d, *J* = 8.1 Hz, 1H, H-1'''), 4.88 (s, 1H), 4.87 (s, 1H), 4.84–4.71 (m, 7H), 4.65 (s, 1H), 4.63 (s, 1H), 4.55 (d, *J* = 11.7 Hz, 1H), 4.50 (d, *J* = 11.7 Hz, 1H), 4.48 (d, *J* = 6.9 Hz, 1H, H-1'''), 4.40 (d, *J* = 7.3 Hz, 1H, H-1'), 4.39–4.33 (m, 3H), 4.29–4.22 (m, 3H, *J* = 7.3 Hz, H-1), 4.14–3.92 (m, 11H), 3.87 (d, *J* = 11.7 Hz, 1H), 3.82–3.65 (m, 4H), 3.63–3.57 (m, 3H), 3.55–3.34 (m, 6H), 3.33–3.26 (m, 3H), 2.92 (s, 1H), 1.53 (s, 3H, NHAc); ¹³C NMR (150 MHz, CDCl₃): δ 171.7, 139.3, 138.6, 138.4, 138.1, 137.8, 129.0, 128.8, 128.5, 128.4, 128.3, 128.1, 127.8, 127.6, 127.1, 126.6, 126.3, 126.2, 104.6, 103.5, 103.1, 101.1, 100.9, 100.7, 100.6, 100.4, 82.0, 81.6, 81.3, 78.9, 78.5, 76.4, 75.7, 75.3, 75.1, 74.9, 74.3, 74.0, 73.5, 73.1, 72.9, 72.0, 71.6, 69.8, 69.3, 69.1, 68.4, 68.0, 67.1, 66.6, 63.1, 53.9, 51.0, 23.4; MALDI TOF MS (positive mode): calcd for C₁₁₁H₁₁₈N₄NaO₂₆ [M + Na]⁺ *m/z*, 1947.140; found, 1947.341; and HRMS (ESI TOF): calcd for C₁₁₁H₁₁₈N₄NaO₂₆ [M + Na]⁺ *m/z*, 1945.7932; found, 1945.8005.

2-Azidoethyl 2,3,6-tri-*O*-phenylmethyl- α -l-fucopyranosyl-(1 \rightarrow 2)-3-*O*-phenylmethyl-4:6-*O*-phenylmethylene- β -D-galactopyranosyl-(1 \rightarrow 3)-2-acetamido-2-deoxy-4:6-*O*-phenylmethylene- β -D-galactopyranosyl-(1 \rightarrow 3)-2-*O*-phenylmethyl-4:6-*O*-phenylmethylene- α -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-phenylmethyl- β -D-galactopyranosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-phenylmethyl- β -D-glucopyranoside 22

After the mixture of **4** (154 mg, 0.293 mmol), **22** (225 mg, 0.117 mmol) and **4 Å MS** (3 g) in CH₂Cl₂ (20 mL) was stirred at rt under an Ar atmosphere for 1 h, it was cooled to –50 °C, and then NIS (79 mg, 0.531 mmol) and TfOH (1.04 μ L, 0.012 mmol) were added. The mixture was allowed to warm up to –30 °C and was stirred at this temperature for 2 h. When TLC showed the completion of reaction, saturated aq. NaHCO₃ solution was added to quench the reaction, and CH₂Cl₂ was then added for dilution. Molecular sieves were removed by passing the mixture through a Celite pad. After extraction with CH₂Cl₂ (3 \times 10), the organic phases were combined and washed with saturated aq. Na₂S₂O₃ solution, dried over Na₂SO₄, and then concentrated in vacuum. The crude product was purified by silica gel column chromatography (acetone–hexane 1 : 6, v/v) to give **22** (192 mg, 70%) as colorless syrup. $[\alpha]_D^{25} = +29.1^\circ$ (*c* 2.66, CHCl₃). ¹H NMR (500 MHz, CDCl₃): δ 7.56–7.49 (m, 3H), 7.46 (d, *J* = 7.3 Hz, 2H), 7.43–7.12 (m, 65H), 5.60 (d, *J* = 3.7 Hz, 1H, H-1'''), 5.56 (d, *J* = 7.9 Hz, 1H, –NHAc), 5.51 (s, 1H), 5.45 (s, 1H), 5.39 (s, 1H), 5.13 (d, *J* = 3.1 Hz, 1H, H-1''), 5.09 (d, *J* = 8.1 Hz, 1H, H-1'''), 5.03 (d, *J* = 11.6 Hz, 1H), 4.91 (d, *J* = 11.0 Hz, 2H), 4.87–4.75 (m, 6H), 4.74–4.56 (m, 7H), 4.55–4.41 (m, 7H, H-1''', H-1', H-1), 4.38 (d, *J* = 12.2 Hz, 1H), 4.35–4.28 (m, 3H), 4.21–4.15 (m, 2H), 4.14–3.80 (m, 14H), 3.78–3.68 (m, 3H), 3.67–3.36 (m, 12H), 3.35–3.26 (m, 4H), 2.93 (s, 1H), 1.44 (s, 3H, –NHAc), 0.72 (d, *J* = 6.1 Hz, 3H, H-6'''); ¹³C NMR (125 MHz, CDCl₃): δ 170.9, 139.3, 139.1, 139.0, 138.8, 138.6, 138.5, 138.4, 138.3, 138.2, 138.1, 137.7, 129.0, 128.9, 128.7, 128.4, 128.37, 128.31, 128.27, 128.2, 128.04, 128.0, 127.9, 127.8, 127.6, 127.5, 127.4, 127.3, 127.2, 127.1, 126.6, 126.5, 126.2, 103.5, 102.1, 101.0, 100.9, 100.8, 100.7,

100.6, 96.3, 82.0, 81.7, 81.3, 79.0, 78.1, 77.4, 77.2, 75.9, 75.8, 75.5, 75.1, 74.9, 74.7, 74.5, 74.0, 73.5, 73.2, 73.1, 72.9, 72.8, 72.7, 72.14, 72.09, 72.02, 70.8, 70.5, 69.3, 69.2, 68.4, 68.0, 67.2, 66.6, 6.4, 66.1, 63.1, 54.6, 51.0, 23.4, 16.1; MALDI TOF MS (positive mode): calcd for C₁₃₈H₁₄₆N₄NaO₃₀ [M + Na]⁺ *m/z*, 2363.640; found, 2364.063; and HRMS (ESI TOF): calcd for C₁₃₈H₁₄₆N₄NaO₃₀ [M + Na]⁺ *m/z*, 2361.9920; found, 2361.9929.

2-Aminoethyl α -l-fucopyranosyl-(1 \rightarrow 2)- β -D-galactopyranosyl-(1 \rightarrow 3)- β -D-galactopyranosyl-(1 \rightarrow 3)- α -D-galactopyranosyl-(1 \rightarrow 4)- β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranoside 2

The solution of **22** (80 mg) dissolved in AcOH and H₂O (5 : 1, 5 mL) was heated at 60 °C for 12 h, at which point MALDI TOF MS [positive mode: calcd for C₁₃₈H₁₄₆N₄O₃₀ [M + Na]⁺ *m/z*, 2099.3; found, 2100.4] confirmed the removal of all benzylidene groups. The solvent was removed in vacuum and the residue was co-evaporated with toluene 5 times to afford a solid product, which was briefly purified by passing through a short silica gel column with *n*-hexane and ethyl acetate (2 : 1 to 1 : 2) as the eluent. The product (30.0 mg, 14 μ mol) was mixed with 10% Pd–C (20.0 mg) in MeOH and H₂O (4 : 1, 10 mL), and the mixture was shaken under a H₂ atmosphere at 50 psi for 48 h. The catalyst was removed by filtration through a Celite pad and the pad was subsequently washed with a mixture of MeOH and H₂O (1 : 1). The combined filtrate was concentrated under vacuum and the residue was dissolved in 2 mL of H₂O and lyophilized to provide the crude product, which was purified twice with a sephadex G-25 gel filtration column using water as the eluent followed by lyophilization to afford **2** (16.2 mg, 50%) as a white solid. $[\alpha]_D^{25} = +9.8^\circ$ (*c* 0.4, H₂O). ¹H NMR (600 MHz, D₂O): δ 5.04 (d, *J* = 3.7 Hz, 1H, H-1'''), 4.70 (d, *J* = 2.9 Hz, 1H, H-1''), 4.43 (d, *J* = 7.3 Hz, 1H, H-1'''), 4.38–4.34 (m, 2H, H-1''', H-1), 4.33 (d, *J* = 7.3 Hz, 1H, H-1'), 4.23–4.18 (m, 1H), 4.07–4.02 (m, 2H), 3.97–3.90 (m, 2H), 3.86–3.69 (m, 7H), 3.68–3.63 (m, 3H), 3.62–3.38 (m, 19H), 3.19 (d, *J* = 8.1 Hz, 1H), 3.10–3.06 (m, 2H), 1.86 (s, 3H, –NHAc), 1.03 (d, *J* = 6.6 Hz, 3H, H-6'''); ¹³C NMR (125 MHz, D₂O): δ 174.2, 103.9, 103.2, 102.0, 101.8, 100.4, 99.2, 78.6, 78.2, 77.1, 76.3, 76.0, 75.4, 75.0, 74.7, 74.5, 74.2, 73.5, 72.7, 72.0, 71.8, 70.8, 70.1, 69.4, 69.1, 69.0, 68.4, 68.0, 67.7, 66.7, 65.7, 60.9, 60.8, 60.3, 58.9, 51.6, 39.3, 22.2, 15.2; MALDI TOF MS (positive mode): calcd for C₄₀H₇₀N₂NaO₃₀ [M + Na]⁺ *m/z*, 1081.98; found, 1081.991; and HRMS (ESI TOF): calcd for C₄₀H₇₁N₂O₃₀ [M + H]⁺ *m/z*, 1059.4092; found, 1059.4089.

Acknowledgements

This work was supported by an NIH/NCI grant (R01 CA95142). The authors thank Dr B. Ksebati (WSU) for some of the 2D NMR measurements. The 600 MHz NMR instrument used in this research was financed by an NSF grant (CHE-0840413).

References

- 1 E. G. Bremer, S. B. Levery, S. Sonnino, R. Ghidoni, S. Canevari, R. Kannagi and S. Hakomori, *J. Biol. Chem.*, 1984, **259**, 14773–14777.

- 2 R. Kannagi, S. B. Levery, F. Ishigami, S. Hakomori, L. H. Shevinsky, B. B. Knowles and D. Solter, *J. Biol. Chem.*, 1983, **258**, 8934–8942.
- 3 S. Menard, E. Tagliabue, S. Canevari, G. Fossati and M. I. Colnaghi, *Cancer Res.*, 1983, **43**, 1295–1300.
- 4 P. O. Livingston, *Semin. Cancer Biol.*, 1995, **6**, 357–366.
- 5 T. Gilewski, G. Ragupathi, S. Bhuta, L. J. Williams, C. Musselli, X. Zhang, K. P. Bencsath, K. S. Panageas, J. Chin, C. A. Hudis, L. Norton, A. N. Houghton, P. O. Livingston and S. J. Danishefsky, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 3270–3275.
- 6 G. Ragupathi, T. Y. Park, S. Zhang, I. J. Kim, L. Graber, S. Aluri, K. O. Lloyd, S. J. Danishefsky and P. O. Livingston, *Angew. Chem., Int. Ed.*, 1997, **36**, 125–128.
- 7 S. F. Slovin, G. Ragupathi, S. Adluri, G. Ungers, K. Terry, S. Kim, M. Spassova, W. G. Bornmann, M. Fazzari, L. Dantis, K. Olkiewicz, K. O. Lloyd, P. O. Livingston, S. J. Danishefsky and H. I. Scher, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 5710–5715.
- 8 W. W. Chang, C. H. Lee, P. S. Lee, J. W. Lin, C. W. Hsu, J. T. Hung, J. J. Lin, J. C. Yu, L. E. Shao, J. Yu, C. H. Wong and A. L. Yu, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 17206.
- 9 H. Y. Lee, C. Y. Chen, T. I. Tsai, S. T. Li, K. H. Lin, Y. Y. Cheng, C. T. Ren, T. J. Cheng, C. Y. Wu and C. H. Wong, *J. Am. Chem. Soc.*, 2014, **136**, 16844–16853.
- 10 Y. L. Huang, J. T. Hung, S. K. Cheung, H. Y. Lee, K. C. Chu, S. T. Li, Y. C. Lin, C. T. Ren, T. J. Cheng, T. L. Hsu, A. L. Yu, C. Y. Wu and C. H. Wong, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 2517–2522.
- 11 C. C. Wang, Y. L. Huang, C. T. Ren, C. W. Lin, J. T. Hung, J. C. Yu, A. L. Yu, C. Y. Wu and C. H. Wong, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 11661–11666.
- 12 S. J. Danishefsky, Y.-K. Shue, M. N. Chang and C.-H. Wong, *Acc. Chem. Res.*, 2015, **48**, DOI: 10.1021/ar5004187.
- 13 G. Ragupathi, S. F. Slovin, S. Adluri, D. Sames, I. J. Kim, H. M. Kim, M. Spassova, W. G. Bornmann, K. O. Lloyd, H. I. Scher, P. O. Livingston and S. J. Danishefsky, *Angew. Chem., Int. Ed.*, 1999, **38**, 563–566.
- 14 T. K. Park, I. J. Kim, S. H. Hu, M. T. Bilodeau, J. T. Randolph, O. Kwon and S. J. Danishefsky, *J. Am. Chem. Soc.*, 1996, **118**, 11488–11500.
- 15 M. T. Bilodeau, T. K. Park, S. H. Hu, J. T. Randolph, S. J. Danishefsky, P. O. Livingston and S. L. Zhang, *J. Am. Chem. Soc.*, 1995, **117**, 7840–7841.
- 16 J. R. Allen, J. G. Allen, X. F. Zhang, L. J. Williams, A. Zatorski, G. Ragupathi, P. O. Livingston and S. J. Danishefsky, *Chem.–Eur. J.*, 2000, **6**, 1366–1375.
- 17 J. M. Lassaletta and R. R. Schmidt, *Liebigs Ann.*, 1996, 1417–1423.
- 18 T. Zhu and G. J. Boons, *Angew. Chem., Int. Ed.*, 1999, **38**, 3495–3497.
- 19 C. Y. Huang, D. A. Thayer, A. Y. Chang, M. D. Best, J. Hoffmann, S. Head and C. H. Wong, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 15–20.
- 20 F. Burkhardt, Z. Y. Zhang, S. Wacowich-Sgarbi and C. H. Wong, *Angew. Chem., Int. Ed.*, 2001, **40**, 1274–1277.
- 21 Z. Wang, L. Zhou, K. El-Boubbou, X. S. Ye and X. Huang, *J. Org. Chem.*, 2007, **72**, 6409–6420.
- 22 D. M. Su, H. Eguchi, W. Yi, L. Li, P. G. Wang and C. Xia, *Org. Lett.*, 2008, **10**, 1009–1012.
- 23 F. Bosse, L. A. Marcaurelle and P. H. Seeberger, *J. Org. Chem.*, 2002, **67**, 6659–6670.
- 24 D. B. Werz, B. Castagner and P. H. Seeberger, *J. Am. Chem. Soc.*, 2007, **129**, 2770–2771.
- 25 M. Adinolfi, A. Iadonisi, A. Ravidà and M. Schiattarella, *J. Org. Chem.*, 2005, **70**, 5316–5319.
- 26 H. Tanaka, N. Matoba and T. Takahashi, *Chem. Lett.*, 2005, **34**, 400–401.
- 27 Q. L. Wang, J. Xue and Z. W. Guo, *Chem. Commun.*, 2009, 5536–5537.
- 28 Q. Wang, Z. Zhou, S. Tang and Z. Guo, *ACS Chem. Biol.*, 2012, **7**, 235–240.
- 29 Q. Wang, S. A. Ekanayaka, J. Wu, J. Zhang and Z. Guo, *Bioconjugate Chem.*, 2008, **19**, 2060–2067.
- 30 K. Daragics and P. Fugedi, *Tetrahedron*, 2010, **66**, 8036–8046.
- 31 H. Tsukamoto, T. Suzuki and Y. Kondo, *Synlett*, 2007, 3131–3136.
- 32 R. Panchadhayee and A. K. Misra, *Tetrahedron: Asymmetry*, 2009, **20**, 1550–1555.
- 33 J. Vesely, A. Rohlenova, M. Dzoganova, T. Trnka, I. Tislerova, D. Saman and M. Ledvina, *Synthesis*, 2006, 699–705.
- 34 J. Lindberg, S. C. T. Svensson, P. Pahlsson and P. Konradsson, *Tetrahedron*, 2002, **58**, 5109–5117.
- 35 D. K. Baeschlin, A. R. Chaperon, L. G. Green, M. G. Hahn, S. J. Ince and S. V. Ley, *Chem.–Eur. J.*, 2000, **6**, 172–186.
- 36 B. Sun, A. V. Pukin, G. M. Visser and H. Zuillhof, *Tetrahedron Lett.*, 2006, **47**, 7371–7374.
- 37 S. M. Chervin, J. B. Lowe and M. Koreeda, *J. Org. Chem.*, 2002, **67**, 5654–5662.